Multiple Myeloma Stages: What It Means, What to Expect and When to See a Specialist

The letter arrives from the lab before the appointment does. A patient in her sixties reads it at the kitchen table: R-ISS stage II. She has spent twenty years in a world where cancer stage meant one thing, a number that told you how far the tumor had traveled, and stage IV was the one nobody wanted to hear. Now a doctor is going to explain that myeloma has no stage IV, that the roman numeral came from a protein in her blood, and that a chromosome she has never heard of matters more than the size of anything anyone can see on a scan.

That gap between what stage sounds like and what it actually measures is where most of the fear lives. Myeloma is a cancer of plasma cells, the antibody factories of the immune system, and it lives in the bone marrow, a tissue spread through the entire skeleton. You cannot draw a line around it. So doctors stage it differently, and the numbers they use deserve a plain, honest walk-through.

What does "stage" actually mean in multiple myeloma?

With a breast or colon tumor, staging is a map. It asks how large the growth is, whether lymph nodes are involved, and whether cells have reached distant organs. Myeloma breaks that model from the start. Plasma cells normally live throughout the marrow, so a myeloma is already “everywhere” on day one. Mapping it would tell you almost nothing.

Staging instead measures two different things. The first is burden: how much disease is present and how hard it is pressing on the body. The second is biology: how aggressively the abnormal cells are likely to behave, judged mainly by genetic changes inside them. A person can have a heavy burden of slow-behaving disease, or a light burden of fast-behaving disease, and the two situations call for very different conversations.

This is also why myeloma stops at stage III. There is no stage IV, because there is no category for “spread.” Patients sometimes hear “stage III” and mentally translate it into the worst possible news from another cancer’s vocabulary. The translation is wrong. Stage III myeloma means the blood markers and genetics point to a more demanding illness, and it changes how urgently and how intensively a specialist plans care. It does not mean the disease has moved somewhere it should not be.

One more distinction matters. Stage is assigned at diagnosis, before treatment, and it is a forecast, not a verdict. Response to therapy, tracked over months, often ends up saying more about an individual’s future than the number on the first lab letter.

How do you know what stage of multiple myeloma you have?

No single test stages myeloma. A hematologist assembles the picture from three streams of information, usually over one to three weeks.

The first stream is blood. Beta-2 microglobulin is a small protein shed by plasma cells; the more myeloma cells there are and the harder the kidneys are working, the higher it climbs. Albumin, the main protein made by the liver, tends to drop when the body is under inflammatory strain. Lactate dehydrogenase, or LDH, is an enzyme released by rapidly turning-over cells and rises when disease is growing quickly. These three values are the backbone of the staging formula, according to the Cleveland Clinic.

The second stream is the bone marrow itself. A biopsy, usually from the back of the pelvis under local anesthetic, tells the lab what percentage of marrow cells are plasma cells and lets it run genetic tests on those cells. Certain chromosome changes, discussed later, move a person into a higher-risk group regardless of how the blood looks.

The third stream is imaging and organ function: kidney tests, calcium, a blood count for anemia, and skeletal imaging to look for bone thinning or lesions. These do not set the stage number directly under the modern system, but they determine whether the disease is causing damage and therefore whether treatment should begin.

Only when all three are in hand does the specialist assign a stage. If someone tells you a stage from a blood test alone, the marrow results are still pending.

What are the three stages of multiple myeloma under R-ISS?

The Revised International Staging System, published by the International Myeloma Working Group in 2015, is the version most specialists use today. It combines the older blood-based International Staging System with LDH and with high-risk genetic changes, then sorts patients into three groups. The original validation study, available through PubMed, followed more than 3,000 newly diagnosed patients and reported the survival figures in the table below.

R-ISS stage	What defines it	Five-year survival in the 2015 study	Median time before disease progressed
Stage I	Low beta-2 microglobulin, normal albumin, normal LDH, no high-risk chromosome changes	82%	66 months
Stage II	Anything that is neither stage I nor stage III	62%	42 months
Stage III	High beta-2 microglobulin plus either raised LDH or a high-risk chromosome change	40%	29 months

Two honest caveats belong beside those numbers. The patients in that study were treated between 2005 and 2012, and several major classes of therapy have arrived since. Real-world outcomes today are generally better than a decade-old table suggests, though exactly how much better varies by group. Second, stage II is a wide net. It catches people whose blood is borderline and people whose genetics are worrying but whose markers are calm, two quite different situations sharing one label.

Read the table as a starting point for a conversation with your hematologist, not as a prediction about you.

Is the Durie-Salmon staging system still used?

Older patients, or anyone who has read a relative’s records from the 1990s, may run into a different vocabulary: Durie-Salmon stage I, II or III, with an added letter A or B. This system dates to 1975 and stages myeloma by estimating how much tumor is in the body, using hemoglobin, calcium, the amount of abnormal antibody in blood or urine, and the number of bone lesions on X-ray. The letter A means kidney function is preserved; B means it is impaired.

Durie-Salmon was a genuine advance for its time. Its weakness is that it leans on plain X-rays, which miss early bone disease, and on antibody quantities that turn out to predict outcomes less well than the simple blood markers in the newer systems. The Mayo Clinic and most large centers now report R-ISS as the primary stage, sometimes alongside Durie-Salmon for continuity.

Why does this matter to a reader? Because the two systems can disagree. Someone with many bone lesions but favorable genetics might be Durie-Salmon III yet R-ISS I. If two documents in your file carry different roman numerals, that is not a clerical error; it is two instruments measuring different things. Ask which system each refers to, and ask which one your specialist is using to plan care. In 2025 the answer is almost always R-ISS or its newer refinements.

What are MGUS and smoldering myeloma, and are they a "stage zero"?

Myeloma rarely appears out of nowhere. It sits at the end of a spectrum that begins with a condition most people have never heard of until a routine blood test flags it.

Monoclonal gammopathy of undetermined significance, or MGUS, means a small clone of plasma cells is producing an abnormal antibody, but there are too few of them to cause harm and no organ damage exists. MGUS is common; the Mayo Clinic notes it becomes more frequent with age and progresses to myeloma or a related disorder at a rate of roughly 1% per year. Most people with MGUS never develop myeloma.

Smoldering myeloma is the next step: more abnormal plasma cells in the marrow, a larger amount of abnormal antibody, but still no bone, kidney, blood or calcium problems. The risk of progression is higher, on the order of 10% per year in the first five years, then falling. Some people with smoldering disease are followed for many years without treatment; others are watched more closely because specific markers suggest change is coming.

Neither condition is technically a myeloma stage, and neither is a diagnosis of cancer in the usual sense. They are, however, the reason a hematologist may ask to see you every few months when you feel entirely well. That monitoring is not overcaution. It is how the transition to active disease gets caught before a fracture or kidney injury announces it.

How long can you have multiple myeloma without knowing?

Years, in many cases. The MGUS-to-myeloma spectrum unfolds slowly, and the early phase produces nothing a person can feel. Studies that retrospectively tested stored blood samples have found the abnormal antibody present long before diagnosis, which is why a surprising number of myeloma cases are first suspected during unrelated blood work: a slightly high protein level, mild anemia on a routine panel, or kidney values drifting upward.

When symptoms do arrive, they are frustratingly ordinary. The NHS lists persistent bone pain, especially in the back or ribs, tiredness out of proportion to activity, repeated infections, and unexplained weight loss. Any one of these has a dozen more common explanations. A fifty-eight-year-old with low back pain will reasonably assume a disc; a seventy-year-old with fatigue will reasonably blame age. Delays of months between first symptom and diagnosis are common and are not anyone’s fault.

Does the delay change the stage? Not necessarily. Stage depends on blood markers and genetics at the moment of diagnosis, and a slow-behaving myeloma can sit at stage I for a long time. What delay can change is damage: a vertebra that compresses, a kidney that scars. That distinction is the whole argument for taking persistent, unexplained bone pain or fatigue to a primary care clinician and asking for a blood count, kidney panel and calcium. The tests are inexpensive and available in any laboratory.

What do the CRAB criteria mean, and how do they relate to stage?

People often confuse two questions: what stage is it and does it need treatment now. Stage answers the first. The CRAB criteria answer the second.

CRAB is a memory aid for the four ways myeloma damages the body, and the Johns Hopkins overview lays them out plainly:

• Calcium elevation in the blood, released as bone breaks down, causing thirst, confusion and constipation.
• Renal, meaning kidney, impairment, because abnormal antibody fragments clog and injure the filtering units.
• Anemia, because crowded marrow cannot make enough red cells, leading to breathlessness and fatigue.
• Bone lesions, thinned or punched-out areas visible on imaging, which cause pain and fractures.

If any CRAB feature is present and attributable to the plasma cell disorder, the diagnosis is active myeloma and treatment is usually recommended. Since 2014, specialists also count three additional biomarkers, sometimes called SLiM, that identify people at very high risk of imminent damage even before a CRAB event happens: a marrow packed with more than 60% plasma cells, a very lopsided ratio of the two types of antibody light chains, or more than one bone lesion seen on MRI.

Here is the practical point. A person can be R-ISS stage I with clear CRAB damage, needing treatment promptly, or R-ISS stage III genetics with no CRAB features at all, in which case the conversation about timing is more nuanced. Stage tells you about likely trajectory. CRAB tells you whether the body is already paying a price.

What technology sits behind a myeloma stage?

The roman numeral on the lab letter is the visible tip of a considerable amount of instrumentation, and understanding it demystifies the wait for results.

Serum protein electrophoresis separates blood proteins by charge across a gel or capillary; myeloma shows up as a sharp spike, the M-protein, where a healthy sample shows a smooth hump. Immunofixation then identifies which antibody type the clone is producing. Free light chain assays measure the fragments small enough to pass through the kidneys, which is why they are so useful both for diagnosis and for tracking response.

Flow cytometry pushes marrow cells single-file past lasers, reading surface markers to distinguish malignant plasma cells from normal ones. Fluorescence in situ hybridization, or FISH, uses colored DNA probes to light up specific chromosome regions; it is how the lab finds the deletion of part of chromosome 17, or the swap of material between chromosomes 4 and 14 or 14 and 16, that define high-risk disease in R-ISS. Newer centers add gene expression panels and next-generation sequencing, though these are not yet part of the standard stage.

On the imaging side, plain X-rays have largely given way to whole-body low-dose CT, MRI of the spine and pelvis, and PET-CT, which the Cleveland Clinic notes can reveal lesions long before an X-ray would. None of these machines assigns a stage on its own. A hematologist integrates them, which is why staging is a specialist’s judgment as much as a laboratory output.

How long do people live with multiple myeloma?

This is the question underneath every other question, and it deserves a straight answer rather than a soft one.

Population data from the National Cancer Institute’s SEER program, part of the NIH, put the five-year relative survival for myeloma at roughly 60% for people diagnosed in recent years. That figure has climbed substantially over two decades; in the early 2000s it was closer to a third. Myeloma accounts for just under 2% of new cancer diagnoses in the United States, with a median age at diagnosis around 69.

By stage, the 2015 R-ISS validation gave five-year survival of 82%, 62% and 40% for stages I, II and III. Those patients were treated with regimens that have since been improved upon, so the true figures today are likely higher in each group, though no one can say by exactly how much for any individual.

What the averages hide is spread. Some people with stage III disease respond deeply and live well for many years; a smaller number with stage I disease relapse early. Age, kidney function at diagnosis, other health conditions, how completely the disease responds to initial therapy, and whether a person is fit enough for intensive approaches all shift the odds. Myeloma is not usually described as curable with current standard care, and honesty requires saying so. It is increasingly described as a chronic, relapsing illness that many people live with for a long time, through several rounds of treatment and remission.

What is the prognosis for multiple myeloma after age 75?

Roughly a third of people diagnosed with myeloma are 75 or older, so this is not a niche question. The candid answer is that outcomes in this group are, on average, less favorable than in younger patients, but the reasons are more nuanced than age itself.

Older adults are less likely to be offered the most intensive therapies, including high-dose treatment followed by stem cell transplant, because the body’s reserve to tolerate them is lower. They are more likely to have kidney disease, heart disease or diabetes that complicate care and independently affect survival. And clinical trials, which generate the survival statistics, have historically enrolled relatively few people over 75, so the numbers we quote are drawn mostly from younger groups.

Against that, several things have moved in the right direction. Many modern regimens are designed to be gentler and are used successfully in people in their eighties. Specialists now use formal frailty assessments, weighing walking speed, daily function and other illnesses rather than birth date alone, to tailor intensity. A fit 78-year-old and a frail 78-year-old may receive very different plans and have very different prospects.

The MedlinePlus overview emphasizes that goals of care should be discussed openly. For many older patients, the aim is controlling disease, protecting bones and kidneys, and preserving independence for as long as possible. That is a legitimate and often achievable target, and it should be set with the person, not for them.

How does stage change treatment decisions?

Stage shapes intensity and urgency; it does not by itself pick a specific therapy. That decision belongs to the hematologist and rests on genetics, organ function, fitness and personal preference.

Modern myeloma treatment combines several classes of medicine that attack plasma cells through different mechanisms. One class blocks the cell’s protein-recycling machinery so that misfolded proteins pile up and trigger cell death. Another adjusts the immune environment and starves the clone of survival signals. Monoclonal antibodies flag plasma cells by a surface marker so the immune system can clear them. Newer immune therapies engineer or redirect a patient’s own T cells to hunt myeloma. Steroids, long a backbone, suppress plasma cell growth directly. The Johns Hopkins overview describes how these are typically layered in combination rather than used singly.

For people fit enough, an initial phase of combination therapy lasting several months is often followed by high-dose treatment with a stem cell transplant, then a lower-intensity maintenance phase that can continue for years. Higher R-ISS stage and high-risk genetics push specialists toward more intensive combinations and closer monitoring, and toward earlier discussion of clinical trials.

Supportive care runs alongside: bone-strengthening medicines, infection prevention, kidney protection and pain management. These do not depend on stage; anyone with CRAB damage benefits from them.

Which combination, in what sequence and for how long is a decision for the prescribing clinician who knows your genetics, kidneys and goals. A stage is an input to that decision, never a substitute for it.

Can your myeloma stage change over time?

Strictly speaking, no. R-ISS stage is assigned once, at diagnosis, and stays in the record as a baseline. What changes, and what specialists watch far more closely afterward, is response.

Response is graded by how far the M-protein and free light chains fall and how much of the marrow clears. A partial response means the abnormal antibody has dropped by at least half. A complete response means it is no longer detectable by standard tests and the marrow contains fewer than 5% plasma cells. A newer, more sensitive category, minimal residual disease negativity or MRD-negative, means that highly sensitive flow cytometry or sequencing cannot find even one malignant cell among 100,000 or more marrow cells. Achieving deep, sustained responses is consistently associated with longer time before relapse, which is why hematologists sometimes seem more interested in your latest light chain result than in your original stage.

Relapse, when it happens, prompts a fresh assessment. Genetics can evolve; a clone that lacked a high-risk change at diagnosis may acquire one later. Some specialists informally describe a person as having “high-risk disease” at relapse even if the original stage was I. The NHS describes myeloma as a condition that typically alternates between periods of remission and periods of active treatment, and each new phase is planned on current biology rather than the number from years before.

The practical takeaway: keep a copy of your original staging, but pay attention to the trend lines. In myeloma, direction matters more than starting point.

When should you see a specialist about possible myeloma?

Myeloma is a hematologist’s disease, and ideally one seen by a hematologist who treats it regularly. The first step, though, is usually primary care, and knowing what to raise there shortens the road.

Ask to be evaluated if you have persistent, unexplained bone pain lasting more than a few weeks, particularly in the spine or ribs, or pain that wakes you at night. Ask if you are unusually tired, short of breath on modest exertion, or bruising or bleeding more easily. Repeated infections that seem out of character, unexplained weight loss, or a blood test that has shown high protein, high calcium or new kidney impairment are all reasons to request a plasma cell workup. Anyone already told they have MGUS or smoldering myeloma should be under scheduled follow-up and should not skip it because they feel fine.

Seek urgent care the same day for sudden severe back pain with numbness, weakness or loss of bladder or bowel control, which can signal a collapsing vertebra pressing on the spinal cord; for confusion, extreme thirst or vomiting, which can accompany dangerously high calcium; for a fever with shaking chills, since myeloma weakens infection defenses; or for passing very little urine, a sign the kidneys may be failing. The Mayo Clinic lists these among the complications that warrant immediate attention.

Once myeloma is confirmed, ask for referral to a specialist who sees the disease often. Staging is standardized; the judgment about what to do with it is not.

What should you ask at your first hematology appointment?

The first specialist visit after diagnosis is often a blur. A short written list helps, and these questions get at what genuinely drives outcome rather than at the roman numeral alone.

Start with the biology. Which staging system was used, and what were the specific values? Were high-risk chromosome changes found, and which ones? Is there any CRAB damage now, and if so, how much of it is likely to recover with treatment? How well are the kidneys working?

Move to the plan. What is the goal of the first phase of treatment, and roughly how many months will it take? Am I a candidate for a stem cell transplant, and if not, why? What response are you hoping to see, and when will you know? Are there clinical trials appropriate for my situation?

Then the everyday. What symptoms should make me call before the next visit? Which infections should I take precautions against? Is it safe to keep working, exercising, traveling? Who do I contact after hours?

Bring someone to take notes, and ask for a copy of the staging report and genetics results. The MedlinePlus patient pages are a reliable place to read afterward without falling into forums that trade in worst cases.

One opinion, earned from reading a great deal of evidence: the single most useful thing a newly diagnosed person can do is make sure a myeloma-experienced hematologist is directing care. Stage is a number. Expertise is what turns it into a plan.

Frequently asked questions

How long do people live with multiple myeloma?

Five-year relative survival is about 60% in recent US population data, up from roughly a third two decades ago. By R-ISS stage, the 2015 validation study reported 82%, 62% and 40% five-year survival for stages I, II and III, using older treatment regimens. Individual outcomes vary widely with age, kidney function, genetics and how deeply the disease responds to initial therapy, so averages are a starting point for discussion, not a personal forecast.

How do you know what stage of multiple myeloma you have?

Your hematologist assigns a stage after combining blood tests for beta-2 microglobulin, albumin and LDH with genetic testing on plasma cells from a bone marrow biopsy. Stage I requires all markers to be favorable with no high-risk chromosome changes; stage III requires high beta-2 microglobulin plus raised LDH or a high-risk genetic change; everything else is stage II. The results usually take one to three weeks to assemble.

How long can you have multiple myeloma without knowing?

Often for years. Myeloma develops from a precursor called MGUS that causes no symptoms and is frequently found by chance on routine blood work. Early symptoms such as back pain, fatigue and recurring infections are nonspecific and easily attributed to other causes, so delays of months between first symptoms and diagnosis are common. Persistent unexplained bone pain or fatigue warrants a blood count, kidney panel and calcium test.

What is the prognosis for multiple myeloma after age 75?

Outcomes after 75 are on average less favorable than in younger patients, largely because intensive options such as stem cell transplant are less often suitable and other health conditions are more common. Fitness matters more than birth date, however, and specialists now use frailty assessments to tailor treatment. Many people in their late seventies and eighties are treated successfully with gentler combination regimens aimed at controlling disease and preserving independence.

Is stage 3 multiple myeloma terminal?

No. Stage III myeloma indicates higher tumor burden or more aggressive biology, not that the disease has spread beyond treatment. The 2015 R-ISS study found 40% of stage III patients alive at five years with regimens that have since been improved upon, and many people with stage III disease achieve deep remissions. Myeloma is not usually considered curable, but it is increasingly managed as a long-term relapsing illness at every stage.

Why is there no stage 4 multiple myeloma?

Because myeloma staging does not measure spread. Plasma cells normally live throughout the bone marrow, so the disease is already distributed across the skeleton at diagnosis and cannot be mapped the way a solid tumor can. Staging systems instead use blood markers and genetics to estimate burden and aggressiveness, and they divide that spectrum into three groups. Stage III is the highest category.

What is the difference between smoldering myeloma and active myeloma?

Smoldering myeloma means abnormal plasma cells and antibody are present at levels above MGUS, but there is no organ damage: no high calcium, kidney impairment, anemia or bone lesions. Active myeloma means at least one of those CRAB features, or a very high-risk biomarker, is present and treatment is usually recommended. Smoldering disease is monitored closely, and progression risk is about 10% per year in the first five years.

Can multiple myeloma stage go down after treatment?

The formal stage is assigned once at diagnosis and does not change. What changes is response, graded by how far abnormal antibody levels fall and how much marrow clears. A complete response means standard tests no longer detect the M-protein, and MRD-negative means highly sensitive tests find no malignant cells. Deep, sustained responses are associated with longer time before relapse and matter more than the original stage.

What genetic changes make multiple myeloma high risk?

Under R-ISS, three chromosome changes count as high risk: deletion of part of chromosome 17, which removes a key tumor-suppressor gene, and translocations that swap material between chromosomes 4 and 14 or between 14 and 16. These are detected by FISH testing on plasma cells from a bone marrow biopsy. Their presence moves a person toward stage III and prompts more intensive treatment and closer monitoring.

What symptoms of multiple myeloma need urgent care?

Seek same-day care for sudden severe back pain with numbness, leg weakness or loss of bladder or bowel control, which can indicate spinal cord compression; confusion, extreme thirst or vomiting, which can accompany dangerously high calcium; fever with shaking chills, since infection defenses are weakened; or passing very little urine, a sign of kidney failure. These complications can develop quickly and are treatable when caught early.

References

• Multiple Myeloma — Cleveland Clinic
• Multiple Myeloma — NHS
• Multiple Myeloma — MedlinePlus

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.